P364: A PHASE II STUDY OF LOW-INTENSITY CHEMOTHERAPY (MINI-HYPER-CVD) AND PONATINIB FOLLOWED BY BLINATUMOMAB AND PONATINIB IN PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

• Fadi Haddad,
• Elias Jabbour,
• Lewis Nasr,
• Nicholas Short,
• Walid Macaron,
• Cedric Nasnas,
• Marianne Zoghbi,
• Ghayas Issa,
• Musa Yilmaz,
• Naval Daver,
• Naveen Pemmaraju,
• Lucia Masarova,
• Farhad Ravandi,
• Nitin Jain,
• Wuliamatu Deen,
• Christopher Loiselle,
• Lourdes Waller,
• Glenda Banks,
• Rebecca Garris,
• Hagop Kantarjian

Affiliations

Fadi Haddad

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Elias Jabbour

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Lewis Nasr

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Nicholas Short

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Walid Macaron

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Cedric Nasnas

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Marianne Zoghbi

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Ghayas Issa

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Musa Yilmaz

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Naval Daver

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Naveen Pemmaraju

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Lucia Masarova

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Farhad Ravandi

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Nitin Jain

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Wuliamatu Deen

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Christopher Loiselle

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Lourdes Waller

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Glenda Banks

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Rebecca Garris

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Hagop Kantarjian

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States